Assembly Biosciences EBITDA 2010-2024 | ASMB
Assembly Biosciences ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Assembly Biosciences Annual EBITDA
(Millions of US $) |
| 2023 |
$-66 |
| 2022 |
$-93 |
| 2021 |
$-90 |
| 2020 |
$-64 |
| 2019 |
$-104 |
| 2018 |
$-92 |
| 2017 |
$-52 |
| 2016 |
$-45 |
| 2015 |
$-30 |
| 2014 |
$-24 |
| 2013 |
$-20 |
| 2012 |
$-25 |
| 2011 |
$-34 |
| 2010 |
$-2 |
| 2009 |
$-3 |
Assembly Biosciences Quarterly EBITDA
(Millions of US $) |
| 2024-09-30 |
$-12 |
| 2024-06-30 |
$-13 |
| 2024-03-31 |
$-12 |
| 2023-12-31 |
$-21 |
| 2023-09-30 |
$-15 |
| 2023-06-30 |
$-18 |
| 2023-03-31 |
$-19 |
| 2022-12-31 |
$-23 |
| 2022-09-30 |
$-23 |
| 2022-06-30 |
$-24 |
| 2022-03-31 |
$-23 |
| 2021-12-31 |
$-21 |
| 2021-09-30 |
$-19 |
| 2021-06-30 |
$-23 |
| 2021-03-31 |
$-27 |
| 2020-12-31 |
$-39 |
| 2020-09-30 |
$-4 |
| 2020-06-30 |
$7 |
| 2020-03-31 |
$-28 |
| 2019-12-31 |
$-29 |
| 2019-09-30 |
$-26 |
| 2019-06-30 |
$-20 |
| 2019-03-31 |
$-29 |
| 2018-12-31 |
$-27 |
| 2018-09-30 |
$-22 |
| 2018-06-30 |
$-27 |
| 2018-03-31 |
$-17 |
| 2017-12-31 |
$-13 |
| 2017-09-30 |
$-12 |
| 2017-06-30 |
$-14 |
| 2017-03-31 |
$-14 |
| 2016-12-31 |
$-12 |
| 2016-09-30 |
$-12 |
| 2016-06-30 |
$-10 |
| 2016-03-31 |
$-11 |
| 2015-12-31 |
$-8 |
| 2015-09-30 |
$-7 |
| 2015-06-30 |
$-7 |
| 2015-03-31 |
$-7 |
| 2014-12-31 |
$-6 |
| 2014-09-30 |
$-11 |
| 2014-06-30 |
$-3 |
| 2014-03-31 |
$-4 |
| 2013-12-31 |
$-6 |
| 2013-09-30 |
$-5 |
| 2013-06-30 |
$-5 |
| 2013-03-31 |
$-4 |
| 2012-12-31 |
$-4 |
| 2012-09-30 |
$-5 |
| 2012-06-30 |
$-7 |
| 2012-03-31 |
$-8 |
| 2011-12-31 |
$-19 |
| 2011-09-30 |
$-5 |
| 2011-06-30 |
$-7 |
| 2011-03-31 |
$-3 |
| 2010-12-31 |
$-3 |
| 2010-09-30 |
$0 |
| 2010-06-30 |
$0 |
| 2010-03-31 |
$-0 |
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.100B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
